ArticleMediterranean journal of rheumatology2025
The Long-Term Outcomes of Pulmonary Hypertension in Systemic Lupus Erythematosus (SLE-PAH) Vary Among Different Autoantibody-Based Clusters: An Observational, Longitudinal Study Conducted at a Single Centre in India.
Article in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors Associated with Systemic Lupus Erythematosus-Associated Interstitial Lung Disease and Clinical Outcomes: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Autoantibody repertoire in lupus nephritis: from pathogenic mechanisms to clinical integration for precision decision-making.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary arterial hypertension (PAH) is often overlooked in systemic lupus erythematosus (SLE) patients. However, the association between SLE and PAH is gaining attention due to unique mechanisms and treatment responses. Objectives: This study aims to categorise SLE-PAH patients by autoantibody profiles and evaluate long-term outcomes, including mortality and changes in PAH over 12 months. Method: A hospital-based investigation included SLE patients diagnosed with PAH. We analysed mortality, PAH resolution, increases in anti-PAH therapy, and follow-up right ventricular systolic pressure (RVSP) over 12 months. K-means cluster analysis was used for clustering, with regression analyses predicting mortality. Result: Analysing 111 SLE PAH patients revealed three clusters: Cluster 1 (CL1)-Sm-RNP positive (n=48), Cluster 2 (CL2)-no specific autoantibodies (n=36), and Cluster 3 (CL3)-multiple autoantibody positivity (n=27) (Smith, Sm-RNP, nucleosome, histone). Nephritis was significant in CL3 with multiple antibody positivity compared to CL1 and CL2 (p=0.01). CL1 showed a higher baseline mean RVSP (64.5 ± 19.1 (CL1) vs 57.5 ± 12.6 (CL2) vs 50.9 ± 12, p=0.002) and more frequent use of dual anti-PAH therapy (p=0.000). CL2, without any specific antibody, had an earlier onset of PAH (p=0.04). Significant improvement in PAH after withdrawing anti-PAH medication was noted in Cluster 3 (p=0.00). Regression analysis showed that aggressive anti-PAH therapy lowers PAH-related mortality (p=0.01), while nephritis (p=0.012) and positive dsDNA (p=0.009) correlate with higher mortality. Conclusion: This study is the first to analyse SLE-PAH through cluster-based methods. Sm-RNP antibodies indicate more severe disease needing dual therapy, while multiple positive antibodies suggest a better prognosis, with most patients achieving PAH resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.